The“Global Filgrastim Injection market Research Report 2022 to 2027”, the study focuses on the analysis of historical and current market trends, which serves as a foundation for assessing industry ...

NEW YORK, Nov. 30, 2016 /PRNewswire/ -- "Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations" is a comprehensive report on Neupogen and ...

Brand logo for NYPOZI (filgrastim-txid) injection. SAN DIEGO, August 19, 2024 (Newswire.com) - Tanvex BioPharma USA, Inc. (“Tanvex” or the “Company”), a contract development and manufacturing ...

The U.S. FDA approved three biosimilar products from Samsung Bioepis Co. Ltd., Tanvex Biopharma Inc. and Formycon AG as follow-on biologics to Stelara (ustekinumab), Neupogen (filgrastim) and Eylea ...

Releuko ® (filgrastim-ayow), a biosimilar to Neupogen ® (filgrastim), is now available in the US for the treatment of neutropenia. Releuko, a leukocyte growth factor, is indicated to: Decrease the ...

The FDA has approved the CXCR4 antagonist motixafortide (Aphexda) for use with filgrastim (Neupogen) to mobilize stem cells for autologous transplantation in multiple myeloma, BioLineRx announced on ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into ...

- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...

Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings. Biosimilars ...